Table 5. Disease duration of scleroderma (1st non-Raynaud's symptom to the time of muscle biopsy) and its association with histopathologic categories on muscle biopsy and autoantibodies.
| Disease duration if present (in years) | Disease duration if absent (in years) | p-value | |
|---|---|---|---|
| Polymyositis (n=2) | 0.68 ± 0.48 | 4.1 ± 7.0 | 0.05 |
| Dermatomyositis (n=3) | 4.1 ± 0.34 | 3.8 ± 7.2 | 0.88 |
| Necrotizing myopathy (n=9) | 5.7 ± 5.9 | 3.7 ± 7.3 | 0.29 |
| Non-specific myositis (n=15) | 1.6 ± 3.8 | 4.3 ± 8.2 | 0.07 |
| Fibrosing myopathy (n=3) | 4.0 ± 4.1 | 3.9 ± 7.2 | 0.88 |
| Acute denervation (n=3) | 16.4 ± 1.3 | 3.9 ±6.7 | 0.04 |
| Anti-PM-Scl antibody (n=41) | 1.4 ± 1.6 | 6.6 ± 7.2 | 0.002 |
| Anti-RNP (n=40) | 7.0 ± 11.1 | 5.3 ± 5.1 | 0.67 |
| Anti-RNA polymerase 3 (n=38) | 7.0 ± 2.0 | 5.3 ± 7.1 | 0.27 |
| Anti-centromere (n=41) | 9.1 ± 7.8 | 5.6 ± 6.9 | 0.38 |
| Anti-Scl 70 (n=39) | 2.4 ± 1.7 | 6.1 ± 7.3 | 0.02 |